Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 15, 2002

BioPharm International

  • BioPharm International-09-01-2002
  • Volume 15
  • Issue 9

Retrovirus and Parvovirus Clearance from an Affinity Column Product Using Adsorptive Depth Filtration

by Barbara Tipton, Jeri Ann Boose, Joanne Beck, Thomas O'Brien, and William Larsen, CUNO Incorporated Two types of depth filters are studied for their ability to rid protein solutions of retroviruses and parvoviruses. Such filters are relatively economical and easy to use, so as secondary virus-removing devices, they are beneficial for downstream processing of mammalian cell cultures. Results indicate that depth filters are more effective on retroviruses than parvoviruses.

Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.